Mayor Sylvester Turner talked parks, innovation, firefighter salaries, and more at the Greater Houston Partnership's State of the City. Natalie Harms/InnovationMap

In the 2019 State of the City Address hosted by the Greater Houston Partnership on May 20, Mayor Sylvester Turner took the stage at the Marriott Marquis in front of over 1,500 Houstonians.

Some of the obvious topics were of course on the table — pension reform, hurricane recovery, job growth — but Mayor Turner surprised attendees with the announcement of a public-private parks program and again alluded to the re-envisioned of Astroworld.

Here's what all the mayor promised in his address.

Public-private partnerships for Houston parks

Houston's major parks have undergone major transformations lately backed by private investments — Buffalo Bayou Park, Memorial Park Conservancy, and Bayou Greenways 2020, to name a few — but the city would like to shift focus to smaller, neighborhood parks across the city. To do this, Mayor Turner called for 50 companies to sponsor 50 parks.

"Today, I am asking the Greater Houston Partnership, the Houston Parks Board, and the Parks Department, to help me bring together 50 companies to form a citywide coalition for our neighborhood parks — primarily in underserved communities," Mayor Turner says.

Scott McClelland, president of HEB Food and Drug and board chair of the GHP, offered up HEB as a corporate partner for the program on the spot, despite the formal details of the program not yet being disclosed. Mayor Turner did specify that the park sponsorship would be a commitment over a few years.

"The 50 for 50 effort will touch every district in the city. All Houstonians should have easy access to welcoming, well-maintained, safe, and fun parks," he says.

A developed innovation corridor and a resurgence of AstroWorld

In both in his introductory address and fireside chat with McClelland, Mayor Turner talked about the emergence of Houston's innovation ecosystem. He cites the 140 percent increase in technology jobs as well as the 3,000 reported startups that call Houston their home. He mentions that Silicon Valley-based accelerator program Plug and Play is preparing to enter the market and another 25 million investment from the Houston Exponential fund of funds is expected.

"We're not walking; we're sprinting," Mayor Turner says. "There is no better place for an [innovation] ecosystem to take place than Houston."

Mayor Turner also credited Rice University's The Ion project as a major source of growth for the city's innovation ecosystem.

"We are building an innovation hub and corridor — in collaboration with academia, thank you, Rice, for loaning us the Sears building on South Main, and the energy and tech companies."

When discussing the innovation district, the mayor also gave a shout out to Travis Scott for being the "instigator" of a new AstroWorld-like theme park the city has in the works, but no details were disclosed in the address.

Rethinking Houston's transportation system

As Houston's population continues to grow, Houstonians spend more and more time in their cars fighting traffic. The mayor called for action to reimagine Houston's transportation.

"Our city has changed, the region is changing, and our transportation, transit, and mobility must change," he says. "People want options, and we must give them options."

Mayor Turner alluded to the Metro Next plan that will be on the ballot this November. While he didn't go into much detail, he encouraged support for the plan.

A raise for the Houston Fire Department

McClelland started the fireside chat with a question about the state of things after Proposition B's repeal following being deemed unconstitutional. The proposition, which originally passed last fall, would have matched Houston firefighters' salaries with police officers.

The mayor says that with the repeal, no layoffs or job cuts will be made within the Houston Fire Department. He recognizes that firefighters are in need of a raise, but it must be one the city can afford.

"Our firefighters are deserving of a pay raise," Mayor Turner says. "What I've put forth is 9.5 percent over three years, but look, my door is open."

The best is yet to come

Mayor Turner wrapped up his address on a positive note, saying that the city's growth will continue.

"The state of our city is strong, resilient, and sustainable," he says. "The best for us as a city has yet to come."

All of these initiatives on the mayor's agenda are working for toward uniting and enhancing Houston.

"We are building one complete city," he says. "And we work together, we win."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.